Fu, Rui
Xiong, Yuanyuan
Cai, Miao
Li, Fang
Chen, Rongrong
Wu, Yilong
Zhong, Wenzhao
Article History
Received: 27 September 2023
Accepted: 17 January 2024
First Online: 28 May 2024
Compliance with ethics guidelines
: <b>Conflicts of interest</b> Wenzhao Zhong declares speaker fees from AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Hengrui, Merck Sharp & Dohme, Pfizer, Roche, Sanofi. Yilong Wu declares advisory services for AstraZeneca, Boehringer Ingelheim, Novartis, and Takeda; speaker fees from AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Hengrui, Merck Sharp & Dohme, Pfizer, Roche, Sanofi; and grants from AstraZeneca, Boehringer Ingelheim, BMS, Pfizer and Roche outside the submitted work. Yuanyuan Xiong, Miao Cai, Fang Li, and Rongrong Chen are current employees of Geneplus-Beijing Ltd. All financial interests are unrelated to this study. Rui Fu declares that he has no conflict of interest. This study was approved by the Institutional Review Board of the Guangdong Provincial People’s Hospital (No. GDREC2018115H) and the study was performed in accordance with the ethical standards as laid down in the 1975 <i>Declaration of Helsinki</i> and its later amendments. Informed consent was obtained from all patients for being included in the study.